busulfan and Germinoblastoma studies

Research Excerpts

Excerpt	Relevance	Reference
"Thiotepa, busulfan and cyclophosphamide-based intensive chemotherapy is an effective treatment for refractory and recurrent primary central nervous system lymphoma in chemosensitive patients up to 65 years of age."	9.16	Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. ( Bouabdallah, K; Choquet, S; Damaj, G; Delgadillo, D; Dupriez, B; Fourme, E; Ghesquières, H; Gonzalez, A; Hoang-Xuan, K; Houillier, C; Leblond, V; Soussain, C; Taillandier, L; Vargaftig, J, 2012)
" BU, CY and etoposide (BUCYE), followed by auto-SCT (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL)."	9.15	Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. ( Choi, DR; Huh, J; Kim, S; Kim, SW; Lee, DH; Lee, JS; Lee, SW; Sohn, BS; Suh, C; Yoon, DH, 2011)
"We investigated the efficacy and safety of tandem high-dose methotrexate (HD-MTX) induction followed by high-dose busulfan/thiotepa (HD-BuTT) with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiation therapy (WBRT) in patients with newly diagnosed primary central nervous system lymphoma."	9.12	Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol ( Al-Ali, HK; Dölken, G; Haas, A; Helke, K; Herbst, R; Hirt, C; Kiefer, T; Krüger, WH; Lotze, C; Montemurro, M; Niederwieser, D; Schüler, F; Schwenke, M; Theilig, A; Wolf, HH, 2007)
"This phase I/II study evaluated high-dose treosulfan in patients with high-grade lymphoma."	9.11	High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. ( Becker, E; Casper, J; Franke, A; Freund, M; Heim, M; Jentsch-Ullrich, K; Koenigsmann, M; Mohren, M, 2004)
"Forty-one patients with advanced Hodgkin's disease or intermediate or high-grade lymphoma, after having received standard salvage chemotherapy, were treated with a nonablative high-dose regimen of paclitaxel, etoposide and cyclophosphamide (D-TEC) to optimally cytoreduce their disease and simultaneously mobilize peripheral blood stem cells."	9.09	Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma. ( Bilgrami, SA; Bona, RD; Clive, J; Edwards, RL; Feingold, JM; Naqvi, B; Tutschka, PJ, 2001)
"Thirty-four adults with malignant lymphoma at high-risk for relapse were treated on a Phase I-II study of high-dose thiotepa (THIO), busulfan (BU) and cyclophosphamide (CYC) with autologous marrow or peripheral blood stem cell support."	9.08	A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. ( Diener, K; Dimopoulos, M; Giralt, S; Hagemeister, F; Ippoliti, C; Khouri, I; Mehra, R; Nath, R; Przepiorka, D; Samuels, B, 1995)
"In primary central nervous system lymphoma, two-year progression-free survival rates of up to 63 percent have been reported for first-line autologous stem cell transplantation after conditioning with the thiotepa busulfan cyclophosphamide regimen."	8.31	Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma. ( Bérengère, G; Bruno, R; Delphine, L; Jean-Pierre, M; Magalie, J; Patrick, V; Pierre, M; Pierre-Edouard, D, 2023)
"A retrospective analysis was performed of 48 consecutive patients who had undergone HDC/ASCT with TBC (thiotepa, busulfan, cyclophosphamide) conditioning for PCNSL (27 patients), secondary CNS lymphoma (SCNSL) (8 patients), or relapsed disease with CNS involvement (13 patients) from July 2006 to December 2017."	7.96	Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. ( Chute, J; de Vos, S; Eradat, HA; Gaut, D; Grotts, J; Kimaiyo, DK; Romero, T; Schiller, G; Timmerman, J; Young, PA, 2020)
"We investigated the incidence of viral, fungal, bacterial, and parasitic infections observed in 57 patients with central nervous system lymphoma after thiotepa, busulfan, and cyclophosphamide-conditioned autologous stem cell transplantation (TBC-ASCT) and 79 patients with systemic non-Hodgkin lymphoma after traditional carmustine, etoposide, cytarabine, and melphalan-conditioned ASCT (BEAM-ASCT)."	7.88	Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. ( Bhatia, A; Chung, HH; DeAngelis, LM; Giralt, SA; Littmann, ER; Maloy, M; Morjaria, SM; Sauter, CS; Scordo, M; Taur, Y, 2018)
"High-dose therapy and autologous stem cell transplantation (ASCT) with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning has emerged as an effective postinduction treatment strategy for patients with primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL), but it is associated with considerable toxicity and transplantation-related mortality (TRM) in the modern era."	7.85	A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. ( Bhatt, V; Dahi, PB; DeAngelis, LM; Giralt, SA; Hsu, M; Matasar, MJ; Moskowitz, CH; Omuro, AM; Sauter, CS; Scordo, M, 2017)
"Double epigenetic modulation of Gem/Bu/Mel with azacitidine/vorinostat is feasible and highly active in patients with refractory/poor-risk relapsed lymphomas, warranting further evaluation."	7.83	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. ( Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC; Wei, W, 2016)
"The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and methylprednisolone (ESHAP) or with dexamethasone (DHAP) with or without Rituximab (± R) in patients with refractory or a relapsed Primary Central Nervous System Lymphoma (PCNSL)."	7.77	Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. ( Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C, 2011)
"We retrospectively evaluated early and long-term complications of an intensified conditioning regimen consisting of busulfan and etoposide in combination with either nimustine hydrochloride (ACNU) (BVA regimen, n = 18) or melphalan (BVL regimen, n = 34) in 52 children with acute leukemia or non-Hodgkin's lymphoma."	7.74	Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. ( Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S, 2007)
"The combination of busulfan and cyclophosphamide has seldom been employed as a conditioning regimen for patients with lymphoma."	7.69	Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. ( Ball, E; de Magalhaes-Silverman, M; Lister, J; Rybka, W; Wilson, J, 1997)
"We report the immunological studies on three transplantable lymphoma lines that developed when CAF1 mice were injected with busulfan and chloramphenicol."	7.67	Busulfan and chloramphenicol induced T cell lymphoma: cell surface characteristics and functional properties. ( Barone-Varelas, J; Bhoopalam, N; Fried, W; Norgello, H; Price, K, 1986)
" We designed studies to determine whether chloramphenicol further damaged the already defective hematopoietic stem cells of mice that were pretreated with busulfan, and we unexpectedly observed that mice given injections of the combination of busulfan and chloramphenicol developed lymphomas in relatively high incidence."	7.66	Induction of lymphomas in mice by busulfan and chloramphenicol. ( Berman, M; Bhoopalam, N; Cohen, H; Fried, W; Robin, E, 1981)
"The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years."	6.82	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. ( Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF, 2016)
"We retrospectively analyzed 132 malignant lymphoma patients who underwent ASCT."	5.43	High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma. ( Cheong, JW; Hwang, DY; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Lee, JY; Min, YH; Yang, WI, 2016)
" To facilitate a therapeutic dose-monitoring protocol, we transitioned from Bu6 to daily Bu dosing for patients with Hodgkin and non-Hodgkin lymphoma undergoing autologous stem cell transplantation (ASCT)."	5.43	Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. ( Andresen, S; Bolwell, BJ; Carlstrom, KD; Dean, R; Gerds, A; Hamilton, B; Hill, BT; Jagadeesh, D; Kalaycio, M; Liu, H; Majhail, NS; Pohlman, B; Rybicki, L; Sobecks, R, 2016)
"The clinical advantage of pharmacokinetic (PK)-directed-based dosing on intravenous (i."	5.38	Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. ( Ali, Z; Dada, MO; Flowers, CR; Graiser, M; Hutcherson, DA; McMillan, S; Waller, EK; Zhang, H, 2012)
" AlloSCT was composed of RIC with busulfan/fludarabine and tacrolimus, sirolimus, and methotrexate as graft-versus-host disease (GVHD) prophylaxis."	5.20	Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. ( Abramson, J; Antin, JH; Armand, P; Barnes, J; Brown, J; Chen, YB; Cutler, C; Del Rio, C; Driscoll, J; El-Jawahri, A; Fisher, DC; Ho, VT; Hochberg, E; Jacobsen, E; Li, S; McAfee, S; Soiffer, R; Spitzer, TR; Takvorian, R, 2015)
" We evaluated outcomes of 144 lymphoma patients given allogeneic SCT with RIC consisting of fludarabine and treosulfan (FT, n=50), intravenous-busulfan (FB2, n=38) or melphalan (FM, n=56)."	5.20	Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies. ( Avigdor, A; Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R, 2015)
"Thiotepa, busulfan and cyclophosphamide-based intensive chemotherapy is an effective treatment for refractory and recurrent primary central nervous system lymphoma in chemosensitive patients up to 65 years of age."	5.16	Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. ( Bouabdallah, K; Choquet, S; Damaj, G; Delgadillo, D; Dupriez, B; Fourme, E; Ghesquières, H; Gonzalez, A; Hoang-Xuan, K; Houillier, C; Leblond, V; Soussain, C; Taillandier, L; Vargaftig, J, 2012)
" BU, CY and etoposide (BUCYE), followed by auto-SCT (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL)."	5.15	Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. ( Choi, DR; Huh, J; Kim, S; Kim, SW; Lee, DH; Lee, JS; Lee, SW; Sohn, BS; Suh, C; Yoon, DH, 2011)
"We investigated the efficacy and safety of tandem high-dose methotrexate (HD-MTX) induction followed by high-dose busulfan/thiotepa (HD-BuTT) with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiation therapy (WBRT) in patients with newly diagnosed primary central nervous system lymphoma."	5.12	Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol ( Al-Ali, HK; Dölken, G; Haas, A; Helke, K; Herbst, R; Hirt, C; Kiefer, T; Krüger, WH; Lotze, C; Montemurro, M; Niederwieser, D; Schüler, F; Schwenke, M; Theilig, A; Wolf, HH, 2007)
"This phase I/II study evaluated high-dose treosulfan in patients with high-grade lymphoma."	5.11	High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. ( Becker, E; Casper, J; Franke, A; Freund, M; Heim, M; Jentsch-Ullrich, K; Koenigsmann, M; Mohren, M, 2004)
"Forty-one patients with advanced Hodgkin's disease or intermediate or high-grade lymphoma, after having received standard salvage chemotherapy, were treated with a nonablative high-dose regimen of paclitaxel, etoposide and cyclophosphamide (D-TEC) to optimally cytoreduce their disease and simultaneously mobilize peripheral blood stem cells."	5.09	Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma. ( Bilgrami, SA; Bona, RD; Clive, J; Edwards, RL; Feingold, JM; Naqvi, B; Tutschka, PJ, 2001)
"Thirty-four adults with malignant lymphoma at high-risk for relapse were treated on a Phase I-II study of high-dose thiotepa (THIO), busulfan (BU) and cyclophosphamide (CYC) with autologous marrow or peripheral blood stem cell support."	5.08	A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. ( Diener, K; Dimopoulos, M; Giralt, S; Hagemeister, F; Ippoliti, C; Khouri, I; Mehra, R; Nath, R; Przepiorka, D; Samuels, B, 1995)
"In both animal models and human studies in leukemia, residual disease on day 8 following myelosuppressive therapy is in a proliferative phase and therefore may be sensitive to the S-phase specific drug cytarabine."	5.07	Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. ( Chandler, C; Devine, S; Geller, RB; Larson, RA; Myers, S; O'Toole, K; Park, CL; Topper, RL; Williams, SF, 1992)
"In the clinical phase studies, ranimustine showed very excellent responses against chronic myelogenous leukemia, polycythemia vera and thrombocythemia, and moderate responses against lymphoma or myeloma."	5.06	[Ranimustine]. ( Masaoka, T, 1990)
"In primary central nervous system lymphoma, two-year progression-free survival rates of up to 63 percent have been reported for first-line autologous stem cell transplantation after conditioning with the thiotepa busulfan cyclophosphamide regimen."	4.31	Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma. ( Bérengère, G; Bruno, R; Delphine, L; Jean-Pierre, M; Magalie, J; Patrick, V; Pierre, M; Pierre-Edouard, D, 2023)
"A retrospective analysis was performed of 48 consecutive patients who had undergone HDC/ASCT with TBC (thiotepa, busulfan, cyclophosphamide) conditioning for PCNSL (27 patients), secondary CNS lymphoma (SCNSL) (8 patients), or relapsed disease with CNS involvement (13 patients) from July 2006 to December 2017."	3.96	Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. ( Chute, J; de Vos, S; Eradat, HA; Gaut, D; Grotts, J; Kimaiyo, DK; Romero, T; Schiller, G; Timmerman, J; Young, PA, 2020)
"Autologous stem cell transplantation (ASCT) with high-dose thiotepa and busulfan is a treatment option for patients with central nervous system (CNS) lymphoma."	3.96	Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation. ( Aiba, A; Hishizawa, M; Kitano, T; Kondo, T; Nishikori, M; Shimazu, Y; Shindo, T; Takaori-Kondo, A; Wada, F; Watanabe, M, 2020)
"We investigated the incidence of viral, fungal, bacterial, and parasitic infections observed in 57 patients with central nervous system lymphoma after thiotepa, busulfan, and cyclophosphamide-conditioned autologous stem cell transplantation (TBC-ASCT) and 79 patients with systemic non-Hodgkin lymphoma after traditional carmustine, etoposide, cytarabine, and melphalan-conditioned ASCT (BEAM-ASCT)."	3.88	Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. ( Bhatia, A; Chung, HH; DeAngelis, LM; Giralt, SA; Littmann, ER; Maloy, M; Morjaria, SM; Sauter, CS; Scordo, M; Taur, Y, 2018)
"High-dose therapy and autologous stem cell transplantation (ASCT) with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning has emerged as an effective postinduction treatment strategy for patients with primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL), but it is associated with considerable toxicity and transplantation-related mortality (TRM) in the modern era."	3.85	A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. ( Bhatt, V; Dahi, PB; DeAngelis, LM; Giralt, SA; Hsu, M; Matasar, MJ; Moskowitz, CH; Omuro, AM; Sauter, CS; Scordo, M, 2017)
" Here, we employed a lymphoma model to characterize tumor-associated circulating neutrophils, including their sensitivity to 5-fluorouracil (5-FU), busulfan (Bu) or treosulfan (Treo)."	3.83	Suppressive effects of low-dose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice. ( Abedi-Valugerdi, M; Hassan, M; Pillai, PR; Sadeghi, B; Wolfsberger, J; Zhao, Y; Zheng, W, 2016)
"Double epigenetic modulation of Gem/Bu/Mel with azacitidine/vorinostat is feasible and highly active in patients with refractory/poor-risk relapsed lymphomas, warranting further evaluation."	3.83	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. ( Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC; Wei, W, 2016)
"The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and methylprednisolone (ESHAP) or with dexamethasone (DHAP) with or without Rituximab (± R) in patients with refractory or a relapsed Primary Central Nervous System Lymphoma (PCNSL)."	3.77	Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. ( Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C, 2011)
"We retrospectively evaluated early and long-term complications of an intensified conditioning regimen consisting of busulfan and etoposide in combination with either nimustine hydrochloride (ACNU) (BVA regimen, n = 18) or melphalan (BVL regimen, n = 34) in 52 children with acute leukemia or non-Hodgkin's lymphoma."	3.74	Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. ( Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S, 2007)
"The combination of busulfan and cyclophosphamide has seldom been employed as a conditioning regimen for patients with lymphoma."	3.69	Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. ( Ball, E; de Magalhaes-Silverman, M; Lister, J; Rybka, W; Wilson, J, 1997)
"The toxic effects of high-dose busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) with autologous or syngeneic bone marrow rescue were evaluated in 19 patients (11 with acute myelocytic leukemia, one with acute lymphocytic leukemia, one with acute myelofibrosis, two with chronic myelocytic leukemia, one with Hodgkin's disease, and three with non-Hodgkin's lymphoma)."	3.67	Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. ( Braine, HG; Kaizer, H; Lu, C; Santos, GW; Saral, R; Tutschka, PJ, 1984)
"Repeated injections of busulfan (Bu) in CAF1 mice caused a long-lasting (greater than 16 weeks) decrease in their natural killer (NK) cell activity and impaired their resistance to transplantable lymphoma."	3.67	Effects of bone marrow transplantation and polyinosinic-polycytidylic acid (poly I:C) on the rescue of animals from busulfan-induced NK suppression. ( Barone-Verales, J; Benson, D; Bhoopalam, N; Fried, W; Price, K, 1989)
"We report the immunological studies on three transplantable lymphoma lines that developed when CAF1 mice were injected with busulfan and chloramphenicol."	3.67	Busulfan and chloramphenicol induced T cell lymphoma: cell surface characteristics and functional properties. ( Barone-Varelas, J; Bhoopalam, N; Fried, W; Norgello, H; Price, K, 1986)
" We designed studies to determine whether chloramphenicol further damaged the already defective hematopoietic stem cells of mice that were pretreated with busulfan, and we unexpectedly observed that mice given injections of the combination of busulfan and chloramphenicol developed lymphomas in relatively high incidence."	3.66	Induction of lymphomas in mice by busulfan and chloramphenicol. ( Berman, M; Bhoopalam, N; Cohen, H; Fried, W; Robin, E, 1981)
"The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years."	2.82	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. ( Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF, 2016)
"A population pharmacokinetic analysis was performed in 30 patients who received an intravenous busulfan and cyclophosphamide regimen before hematopoietic stem cell transplantation."	2.72	Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. ( Nakashima, D; Takama, H; Takaue, Y; Tanaka, H; Ueda, R, 2006)
"To evaluate the toxic extramedullary morbidity of the conditioning treatment with BuCy for BMT, as well as the usefulness of pentoxyphyllin (PTX) and methylprednisolone (MP) in the prophylaxis of mucositis."	2.39	[Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning]. ( Maldonado, J; Pascual, MJ, 1995)
"Mucositis was the main reported complications and infectious episodes were described in 80."	1.51	BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). ( Alexis, M; Amorim, S; Bay, JO; Chauchet, A; Chrétien, ML; Cluzeau, T; Contentin, N; Cornillon, J; Daguenet, E; de Latour, RP; Dorvaux, V; Gyan, E; Himberlin, C; Huynh, A; Lejeune, C; Mercier, M; Nicolas-Virelizier, E; Salles, G; Vallet, N, 2019)
" To facilitate a therapeutic dose-monitoring protocol, we transitioned from Bu6 to daily Bu dosing for patients with Hodgkin and non-Hodgkin lymphoma undergoing autologous stem cell transplantation (ASCT)."	1.43	Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. ( Andresen, S; Bolwell, BJ; Carlstrom, KD; Dean, R; Gerds, A; Hamilton, B; Hill, BT; Jagadeesh, D; Kalaycio, M; Liu, H; Majhail, NS; Pohlman, B; Rybicki, L; Sobecks, R, 2016)
"We retrospectively analyzed 132 malignant lymphoma patients who underwent ASCT."	1.43	High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma. ( Cheong, JW; Hwang, DY; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Lee, JY; Min, YH; Yang, WI, 2016)
"Among the causes of IRM, bacterial infections and IFIs were more common in sCBT (15% vs."	1.42	Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH). ( Barba, P; Bautista, G; Cabrera, JR; Duarte, R; Esquirol, A; Fores, R; García, I; García-Marco, JA; Heras, I; Marquez-Malaver, FJ; Martino, R; Parody, R; Regidor, C; Rovira, M; Saavedra, S; Sánchez-Ortega, I; Serrano, D; Sierra, J; Vazquez, L, 2015)
"Gemcitabine dose was escalated by extending infusions at a fixed rate of 10 mg/m(2)/min in sequential cohorts, in daily, 3-dose or 2-dose schedules."	1.38	High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. ( Alousi, A; Anderlini, P; Andersson, B; Bashir, Q; Bassett, R; Champlin, R; Chancoco, C; Ciurea, S; Frazier, E; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Khouri, I; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Rondon, G; Shah, N; Shpall, EJ; Thall, P; Valdez, B; Worth, L, 2012)
" In an attempt to design an efficacious and safe prehematopoietic stem cell transplantation conditioning regimen, we investigated the cytotoxicity of the combination of busulfan (B), melphalan (M), and gemcitabine (G) in lymphoma cell lines in the absence or presence of drugs that induce epigenetic changes."	1.38	Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. ( Andersson, BS; Champlin, RE; Li, Y; Murray, D; Nieto, Y; Valdez, BC; Wang, G, 2012)
"The clinical advantage of pharmacokinetic (PK)-directed-based dosing on intravenous (i."	1.38	Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. ( Ali, Z; Dada, MO; Flowers, CR; Graiser, M; Hutcherson, DA; McMillan, S; Waller, EK; Zhang, H, 2012)
" Mice (n = 64/65) were dosed 10 times with BU at 0 (vehicle control), 8."	1.33	Further development of a model of chronic bone marrow aplasia in the busulphan-treated mouse. ( Andrews, CM; Gibson, FM; Gordon-Smith, EC; Molyneux, G; Pilling, AM; Rizzo, S; Sones, WR; Turton, JA; Williams, TC, 2006)
"Data on 181 of 230 patients with aplastic anemia, leukemias, and lymphomas who had BMT before puberty (mean age, 9."	1.30	Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. ( Bakker, B; Cahn, JY; Cohen, A; Dopfer, R; Esperou, H; Gaiero, A; Kolb, HJ; Leiper, AD; Merlo, F; Rovelli, A; Socié, G; Uderzo, C; van Lint, MT, 1999)
" There were seven acute toxic deaths (8%) and in total 15 patients experienced life-threatening or fatal toxicity."	1.29	Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. ( Bernstein, E; Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Mullaney, R; Resnick, K; Styler, MJ; Topolsky, D, 1995)
"Although toxicities with bone marrow transplant preparative regimens containing etoposide in combination with cyclophosphamide and total body irradiation or busulfan were frequently severe, treatment related mortality risk was believed to be acceptably low."	1.29	Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children. ( Cahill, R; Deeg, HJ; Gadner, H; Ortlieb, M; Peters, C; Spitzer, TR; Tefft, MC; Torrisi, J; Urban, C, 1994)
"Of 602 patients treated for non-Hodgkin's lymphomas, 9 developed overt acute nonlymphocytic leukemia or preleukemia with refractory cytopenia and cytogenetic abnormalities of the bone marrow."	1.27	Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. ( Ersbøll, J; Keiding, N; Larsen, MS; Larsen, SO; Nissen, NI; Pedersen-Bjergaard, J; Philip, P; Schultz, H; Sørensen, HM, 1985)

Research

Studies (113)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Cumulative Incidence of Disease Relapse

Cumulative Incidence of Extensive Chronic Graft-versus-host-disease

Timeframe	Studies, this research(%)	All Research%
pre-1990	37 (32.74)	18.7374
1990's	23 (20.35)	18.2507
2000's	14 (12.39)	29.6817
2010's	33 (29.20)	24.3611
2020's	6 (5.31)	2.80

Authors	Studies
Kim, KH	1
Lee, JH	1
Lee, M	2
Kim, HG	1
Do, YR	1
Park, Y	1
Oh, SY	1
Shin, HJ	1
Kim, WS	1
Park, SK	1
Kong, JH	1
Park, MR	1
Yang, DH	1
Kwak, JY	1
Kang, HJ	1
Mun, YC	1
Won, JH	1
Schenone, L	1
Houillier, C	2
Tanguy, ML	1
Choquet, S	3
Agbetiafa, K	1
Ghesquières, H	2
Damaj, G	2
Schmitt, A	1
Bouabdallah, K	2
Ahle, G	1
Gressin, R	1
Cornillon, J	2
Houot, R	1
Marolleau, JP	1
Fornecker, LM	1
Chinot, O	1
Peyrade, F	1
Bouabdallah, R	1
Moluçon-Chabrot, C	1
Gyan, E	2
Chauchet, A	2
Casasnovas, O	1
Oberic, L	1
Delwail, V	1
Abraham, J	1
Roland, V	2
Waultier-Rascalou, A	1
Willems, L	1
Morschhauser, F	1
Fabbro, M	1
Ursu, R	1
Thieblemont, C	1
Jardin, F	1
Tempescul, A	1
Malaise, D	1
Touitou, V	1
Nichelli, L	1
Le Garff-Tavernier, M	1
Plessier, A	1
Bourget, P	1
Bonmati, C	1
Wantz-Mézières, S	1
Giordan, Q	1
Dorvaux, V	2
Charron, C	1
Jabeur, W	1
Hoang-Xuan, K	3
Taillandier, L	2
Soussain, C	3
Delphine, L	1
Pierre-Edouard, D	1
Bruno, R	1
Bérengère, G	1
Magalie, J	1
Patrick, V	1
Jean-Pierre, M	1
Pierre, M	1
Young, PA	1
Gaut, D	1
Kimaiyo, DK	1
Grotts, J	1
Romero, T	1
Chute, J	1
Schiller, G	1
de Vos, S	1
Eradat, HA	1
Timmerman, J	1
Wada, F	1
Nishikori, M	1
Hishizawa, M	1
Watanabe, M	1
Aiba, A	1
Kitano, T	1
Shimazu, Y	1
Shindo, T	1
Kondo, T	1
Takaori-Kondo, A	1
Hill, JM	1
Meehan, KR	1
DeFilipp, Z	1
Li, S	2
El-Jawahri, A	2
Armand, P	3
Nayak, L	1
Wang, N	1
Batchelor, TT	1
Chen, YB	2
Valdez, BC	5
Li, Y	4
Murray, D	3
Liu, Y	2
Nieto, Y	6
Champlin, RE	4
Andersson, BS	5
Rajagopal, R	1
Miles, GCP	1
Kotecha, RS	1
Scordo, M	2
Morjaria, SM	1
Littmann, ER	1
Bhatia, A	1
Chung, HH	1
Maloy, M	1
DeAngelis, LM	2
Giralt, SA	2
Taur, Y	1
Sauter, CS	2
Marinho-Dias, J	1
Lobo, J	1
Henrique, R	1
Baldaque, I	1
Pinho-Vaz, C	1
Regadas, L	1
Branca, R	1
Campilho, F	1
Campos, A	1
Medeiros, R	1
Sousa, H	1
Huang, H	1
Zhang, L	1
Jiang, Y	1
Liu, S	1
Jin, Z	1
Chen, J	1
Xiao, X	1
Ruan, J	1
Zhang, X	1
Wu, D	1
Sanders, S	1
Chua, N	2
Larouche, JF	1
Owen, C	1
Shafey, M	1
Stewart, DA	3
Hyung, J	1
Hong, JY	1
Yoon, DH	2
Kim, S	2
Park, JS	1
Park, CS	1
Lee, SW	2
Kim, JH	1
Ryu, JS	1
Huh, J	2
Suh, C	2
Daguenet, E	1
Bay, JO	1
Salles, G	1
Contentin, N	1
Nicolas-Virelizier, E	1
Mercier, M	1
Vallet, N	1
Alexis, M	1
Chrétien, ML	1
Cluzeau, T	1
Huynh, A	1
Himberlin, C	1
Amorim, S	1
Lejeune, C	1
de Latour, RP	1
Boysen, G	1
Shimoni, A	2
Danylesko, I	2
Varda-Bloom, N	1
Nagler, A	3
Hori, D	1
Kobayashi, R	1
Fujita, N	2
Suzumiya, J	1
Suzuki, R	1
Kato, K	2
Kawata, T	1
Fukuda, T	1
Inoue, M	1
Goto, H	3
Hama, A	1
Iwato, K	1
Okumura, H	1
Eto, T	1
Hashii, Y	1
Atsuta, Y	1
Mitsui, T	1
Martino, R	2
Bautista, G	1
Parody, R	1
García, I	1
Esquirol, A	2
Rovira, M	1
Cabrera, JR	1
Regidor, C	1
Fores, R	1
García-Marco, JA	1
Serrano, D	1
Barba, P	1
Heras, I	1
Marquez-Malaver, FJ	2
Sánchez-Ortega, I	1
Duarte, R	1
Saavedra, S	1
Sierra, J	1
Vazquez, L	1
Oh, DH	1
Street, L	1
Hwang, DY	1
Kim, SJ	1
Cheong, JW	1
Kim, Y	1
Jang, JE	1
Lee, JY	1
Min, YH	1
Yang, WI	1
Kim, JS	1
Fisher, DC	1
Driscoll, J	1
Del Rio, C	1
Abramson, J	1
Barnes, J	1
Brown, J	1
Cutler, C	1
Ho, VT	1
Hochberg, E	1
McAfee, S	1
Takvorian, R	1
Spitzer, TR	2
Antin, JH	2
Soiffer, R	1
Jacobsen, E	1
Yerushalmi, R	1
Shem-Tov, N	1
Avigdor, A	1
Ji, J	1
Teo, EC	1
Flowers, CR	2
Costa, LJ	1
Pasquini, MC	1
Le-Rademacher, J	1
Lill, M	1
Shore, TB	1
Vaughan, W	1
Craig, M	1
Freytes, CO	1
Shea, TC	1
Horwitz, ME	1
Fay, JW	1
Mineishi, S	1
Rondelli, D	1
Mason, J	1
Braunschweig, I	1
Ai, W	1
Yeh, RF	1
Rodriguez, TE	1
Flinn, I	1
Comeau, T	1
Yeager, AM	1
Pulsipher, MA	1
Bence-Bruckler, I	1
Laneuville, P	1
Bierman, P	1
Chen, AI	1
Wang, Y	1
Xu, C	1
Smith, AJ	1
Waller, EK	2
Thall, PF	1
Jones, RB	2
Wei, W	1
Myers, A	1
Hosing, C	2
Ahmed, S	1
Popat, U	2
Shpall, EJ	2
Qazilbash, M	2
Gulbis, A	2
Anderlini, P	2
Shah, N	2
Bashir, Q	2
Alousi, A	2
Oki, Y	1
Fanale, M	1
Dabaja, B	1
Pinnix, C	1
Champlin, R	2
Hill, BT	1
Rybicki, L	1
Carlstrom, KD	1
Jagadeesh, D	1
Gerds, A	1
Hamilton, B	1
Liu, H	1
Dean, R	1
Sobecks, R	1
Pohlman, B	1
Andresen, S	1
Kalaycio, M	1
Bolwell, BJ	1
Majhail, NS	1
Kekre, N	1
Cabrero, M	1
Piñana, J	1
Soiffer, RJ	1
Caballero, D	1
Terol, MJ	1
Lopez-Corral, L	1
Solano, C	1
Pérez-Simon, JA	1
Abedi-Valugerdi, M	1
Wolfsberger, J	1
Pillai, PR	1
Zheng, W	1
Sadeghi, B	1
Zhao, Y	1
Hassan, M	1
Bhatt, V	1
Hsu, M	1
Omuro, AM	1
Matasar, MJ	1
Dahi, PB	1
Moskowitz, CH	1
Lee, DH	1
Choi, DR	1
Sohn, BS	1
Kim, SW	1
Lee, JS	1
Pidala, J	1
Roman-Diaz, J	1
Kim, J	1
Nishihori, T	1
Perkins, J	1
Tate, C	1
Ochoa-Bayona, JL	1
Field, T	1
Fernandez, HF	1
Tomblyn, M	1
Ayala, E	1
Anasetti, C	1
Kharfan-Dabaja, MA	1
Malard, F	1
Cahu, X	1
Clavert, A	2
Brissot, E	1
Chevallier, P	2
Guillaume, T	2
Delaunay, J	2
Ayari, S	2
Dubruille, V	2
Mahe, B	2
Gastinne, T	2
Blin, N	2
Harousseau, JL	1
Moreau, P	2
Miplied, N	1
Le Gouill, S	2
Mohty, M	2
del Rio, MS	1
Glaisner, S	1
Fourme, E	2
Janvier, M	1
Wang, G	2
Zhang, H	1
Graiser, M	1
Hutcherson, DA	1
Dada, MO	1
McMillan, S	1
Ali, Z	1
Delgadillo, D	1
Dupriez, B	1
Vargaftig, J	1
Gonzalez, A	1
Leblond, V	1
Thall, P	1
Valdez, B	1
Andersson, B	2
Bassett, R	1
Kebriaei, P	1
Frazier, E	1
Chancoco, C	1
Ciurea, S	1
Khouri, I	2
Parmar, S	1
Worth, L	1
Rondon, G	1
Le Bourgeois, A	1
Lestang, E	1
Tessoulin, B	1
Planche, L	1
Ritchie, DS	1
Szer, J	1
Roberts, AW	1
Shuttleworth, P	1
Grigg, AP	1
Cheng, T	1
Forsyth, P	1
Chaudhry, A	1
Morris, D	1
Glück, S	1
Russell, JA	1
SYKES, MP	1
PITNEY, WR	1
OSSIPOVSKI, B	1
WEBER, RE	1
HELMAN, N	1
ROSSOLIMO, OK	2
LEPESHKINA, GN	1
CHORIN, VA	1
GOLDBERG, LE	1
STANISLAVSKAYA, MS	1
BLUMBERG, NA	1
VERTOGRADOVA, TP	1
CLIFFORD, P	1
HUTCHISON, JL	1
CONKLIN, JW	1
UPTON, AC	1
CHRISTENBERRY, KW	1
MORROW, LB	1
ANDERSON, RE	1
PETERS, RL	1
Casper, J	2
Knauf, W	1
Blau, I	1
Ruutu, T	2
Volin, L	2
Wandt, H	1
Schafer-Eckart, K	1
Holowiecki, J	1
Giebel, S	1
Aschan, J	1
Zander, A	1
Kroger, N	1
Doelken, G	1
Freund, M	2
Koenigsmann, M	1
Mohren, M	1
Jentsch-Ullrich, K	1
Franke, A	1
Becker, E	1
Heim, M	1
Spyridonidis, A	1
Küttler, T	1
Wäsch, R	1
Samek, E	1
Waterhouse, M	1
Behringer, D	1
Bertz, H	1
Finke, J	2
Takama, H	1
Tanaka, H	1
Nakashima, D	1
Ueda, R	1
Takaue, Y	1
Turton, JA	1
Sones, WR	1
Andrews, CM	1
Pilling, AM	1
Williams, TC	1
Molyneux, G	1
Rizzo, S	1
Gordon-Smith, EC	1
Gibson, FM	1
Montemurro, M	1
Kiefer, T	1
Schüler, F	1
Al-Ali, HK	1
Wolf, HH	1
Herbst, R	1
Haas, A	1
Helke, K	1
Theilig, A	1
Lotze, C	1
Hirt, C	1
Niederwieser, D	1
Schwenke, M	1
Krüger, WH	1
Dölken, G	1
Izaki, S	1
Okuda, K	1
Matsuda, M	1
Watanabe, Y	1
Fujioka, K	1
Hanzawa, N	1
Sumita, H	1
Takahashi, H	1
Goto, S	1
Kai, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612]		50 participants (Anticipated)	Observational	2024-01-01	Not yet recruiting
Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas[NCT01181271]	Phase 2	42 participants (Actual)	Interventional	2010-08-31	Completed
Addition of Gemcitabine to the Standard Reduced Busulfan and Cyclophosphamide (BUCY2) Pre Allogeneic Hematopoietic Stem Cell Transplantation Conditioning for Acute Lymphoblastic Leukemia[NCT03339700]	Phase 2	15 participants (Anticipated)	Interventional	2018-09-15	Recruiting
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793]	Phase 2	11 participants (Actual)	Interventional	2010-10-14	Terminated (stopped due to The clinical trial was terminated due to poor enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	percentage of participants (Number)
Autologous Then Allogeneic Transplant	17.2

Extensive chronic graft versus-host-disease (GVHD) was defined as GVHD that required systemic immunosuppression. (NCT01181271)
Timeframe: 1-year after allogeneic transplant

Cumulative Incidence of Grades II to IV Acute Graft Versus Host Disease (GVHD)

Intervention	percentage of participants (Number)
Autologous Then Allogeneic Transplant	37.9

Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening. (NCT01181271)
Timeframe: within 200 days after allogeneic transplant

Cumulative Incidence of Non-relapse Mortality

Intervention	percentage of participants (Number)
Autologous Then Allogeneic Transplant	13.8

Non-relapse mortality is defined as participants who die from causes other than their underlying disease relapse, such as infection or graft versus host disease (NCT01181271)
Timeframe: 2-years after allogeneic transplant

Estimated Two Year Overall Survival Rate for All Participants

Estimated Two Year Overall Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants

Estimated Two Year Overall Survival Rate for Participants Undergoing Only Autologous Transplant

Estimated Two Year Progression Free Survival Rate for All Participants

Estimated Two Year Progression Free Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants

Estimated Two Year Progression Free Survival Rate for Participants Undergoing Only Autologous Transplant

Number of Days After Allogeneic Transplant Until Absolute Neutrophil Count Was Equal to or Greater Than 500/uL

Peripheral Blood All-cell Donor Chimerism

Intervention	percentage of participants (Number)
Autologous Then Allogeneic Transplant	11.1

Intervention	percentage of participants (Number)
Autologous Then Allogeneic Transplant	83

Intervention	percentage of participants (Number)
Autologous Then Allogeneic Transplant	89

Intervention	percentage of participants (Number)
Autologous Then Allogeneic Transplant	69

Intervention	percentage of participants (Number)
Autologous Then Allogeneic Transplant	64

Intervention	percentage of participants (Number)
Autologous Then Allogeneic Transplant	72

Intervention	percentage of participants (Number)
Autologous Then Allogeneic Transplant	46

Intervention	days (Median)
Autologous Then Allogeneic Transplant	12

Successful donor stem cell engraftment is defined as when ≥ 80% of hematopoietic elements are donor-derived as determined by chimerism assays from peripheral blood at day 100 after non-myeloablative allogeneic stem cell transplantation. (NCT01181271)
Timeframe: 100 days post allogeneic transplant

Safest Dose of Temozolomide for the DRBEAT Regimen

Intervention	percentage of donor-derived elements (Median)
Autologous Then Allogeneic Transplant	95

Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year

One-year Progression-free Survival and Overall Survival

Intervention	dose in mg/m^2 (Number)
DRBEAT Regimen	773.25

"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years

Article	Year
[Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning]. Sangre, 1995, Volume: 40, Issue:3 Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Arrhythmias, Cardiac; Bone Marrow Tran	1995
Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies. Bone marrow transplantation, 1994, Volume: 14 Suppl 4 Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr	1994
[Total body irradiation in hematology: clinical indications and prospects]. Recenti progressi in medicina, 1999, Volume: 90, Issue:11 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols	1999
Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood, 1992, Oct-01, Volume: 80, Issue:7 Topics: Animals; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Humans; Immunosuppression Therapy;	1992
Adoptive tumor immunotherapy in mice as an adjunct to whole-body x-irradiation and chemotherapy. A review. Israel journal of medical sciences, 1973, Volume: 9, Issue:3 Topics: Animals; Antigens, Neoplasm; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cyclophospham	1973
The spectrum of diffuse pulmonary infiltration in malignant disease. Chest, 1973, Volume: 64, Issue:1 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Busulfan; Embolism, Fat; Hemorrhage; Hodgkin Disease; Humans; I	1973
[Current status of prognosis and the factors affecting it in adult leukemia and malignant lymphoma]. Naika. Internal medicine, 1967, Volume: 20, Issue:5 Topics: Adolescent; Adult; Busulfan; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloi	1967

Article	Year
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Mul Cancer research and treatment, 2023, Volume: 55, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Behavior Therapy; Busulfan; Cyclophosphamide; Etopos	2023
Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Alberta; Autografts; Busulfan; Central Nervous System Neoplasms; Dis	2019
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:9 Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Disea	2015
Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies. Bone marrow transplantation, 2015, Volume: 50, Issue:12 Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hum	2015
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:7 Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hemat	2016
Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. Bone marrow transplantation, 2011, Volume: 46, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Centra	2011
Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica, 2012, Volume: 97, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla	2012
A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation. Bone marrow transplantation, 2002, Volume: 30, Issue:10 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etopo	2002
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. Annals of hematology, 2004, Volume: 83 Suppl 1 Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplast	2004
High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone marrow transplantation, 2004, Volume: 34, Issue:6 Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Etoposide; Female; Hematopoietic Stem Cell Mobil	2004
Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. Bone marrow transplantation, 2006, Volume: 37, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Fluid Compartments; Body Mas	2006
Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous S	2007
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leukemia & lymphoma, 1995, Volume: 17, Issue:5-6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Chemic	1995
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone marrow transplantation, 1994, Volume: 14, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu	1994
Treatment with erythropoietin after allogeneic bone marrow transplantation: a randomized, double-blind study. Transplantation proceedings, 1994, Volume: 26, Issue:3 Topics: Bone Marrow Transplantation; Busulfan; Costs and Cost Analysis; Double-Blind Method; Erythrocyte Tra	1994
A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies. Transplantation proceedings, 1994, Volume: 26, Issue:3 Topics: Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Humans; Immunosuppression Therapy; Leukemia	1994
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF. Bone marrow transplantation, 1996, Volume: 17, Issue:2 Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Admi	1996
Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone marrow transplantation, 1996, Volume: 17, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan;	1996
Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:6 Topics: Adoptive Transfer; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Busulfan; Cells, Cultured;	1995
Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma. Acta haematologica, 2001, Volume: 105, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined M	2001
Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. Bone marrow transplantation, 1992, Volume: 9, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation	1992
[Ranimustine]. Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:2 Topics: Antineoplastic Agents; Busulfan; Drug Evaluation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Po	1990

Article	Year
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network. Bone marrow transplantation, 2022, Volume: 57, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Centra	2022
Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma. Medical sciences (Basel, Switzerland), 2023, 01-29, Volume: 11, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System; Cyclophospha	2023
Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cy	2020
Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation. International journal of hematology, 2020, Volume: 112, Issue:5 Topics: Adult; Aged; Busulfan; Central Nervous System Neoplasms; Female; Hematopoietic Stem Cell Transplanta	2020
Should Thiotepa-Based Regimens Be the New Transplant Conditioning Strategy for Primary Central Nervous System Lymphoma? JAMA oncology, 2021, 07-01, Volume: 7, Issue:7 Topics: Busulfan; Central Nervous System; Humans; Lymphoma; Thiotepa; Transplantation Conditioning	2021
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer, 2017, Aug-15, Volume: 123, Issue:16 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Busulfan; Central	2017
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leukemia & lymphoma, 2017, Volume: 58, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Line, Tumor; Cell Proliferatio	2017
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for pediatric primary central nervous system lymphoma in first complete remission. Cancer, 2017, 07-15, Volume: 123, Issue:14 Topics: Busulfan; Child; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Thiote	2017
Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:9 Topics: Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Female; Humans; Lymphoma; Male; Middle	2018
Post‑transplant lymphoproliferative disorder in hematopoietic stem cell transplant patients: A single center retrospective study between 2005 and 2012. Molecular medicine reports, 2018, Volume: 18, Issue:5 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Epstein-Barr Virus Infection	2018
Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation. Annals of hematology, 2019, Volume: 98, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Cyclo	2019
Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma. Annals of hematology, 2019, Volume: 98, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System N	2019
BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Annals of hematology, 2019, Volume: 98, Issue:8 Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bus	2019
A simplified method for detection of N-terminal valine adducts in patients receiving treosulfan. Rapid communications in mass spectrometry : RCM, 2019, Nov-15, Volume: 33, Issue:21 Topics: Adult; Aged; Busulfan; Chromatography, Liquid; Female; Hemoglobins; Humans; Leukemia; Lymphoma; Male	2019
The effectiveness of busulfan-based conditioning regimens for stem cell transplantation against lymphomas in children, adolescents, and young adults in Japan. Pediatric blood & cancer, 2019, Volume: 66, Issue:10 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantatio	2019
Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH). Transplant infectious disease : an official journal of the Transplantation Society, 2015, Volume: 17, Issue:2 Topics: Adolescent; Adult; Antigens, CD34; Bacterial Infections; Busulfan; Cohort Studies; Cord Blood Stem C	2015
Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant. Leukemia & lymphoma, 2016, Volume: 57, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined	2016
High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma. Leukemia & lymphoma, 2016, Volume: 57, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Ferritins	2016
Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. Experimental hematology, 2016, Volume: 44, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Busulfan; Cell Line, Tumor; Cell Membrane	2016
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer, 2016, 09-01, Volume: 122, Issue:17 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Chil	2016
Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:9 Topics: Adult; Aged; Busulfan; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Hematopoie	2016
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Graft vs	2016
Suppressive effects of low-dose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice. International immunopharmacology, 2016, Volume: 40 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined	2016
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla	2017
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. International journal of hematology, 2011, Volume: 93, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineop	2011
Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:11 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Hematopoieti	2011
Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. Journal of neuro-oncology, 2011, Volume: 105, Issue:2 Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combin	2011
Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines. Leukemia & lymphoma, 2012, Volume: 53, Issue:5 Topics: Acetylation; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busu	2012
Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Cyclophosphamide; Drug Adm	2012
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Dr	2012
Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Experimental hematology, 2012, Volume: 40, Issue:10 Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Busulfan; Ce	2012
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT). European journal of haematology, 2013, Volume: 90, Issue:3 Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; H	2013
High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone marrow transplantation, 2003, Volume: 31, Issue:8 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Busulfan;	2003
Myleran in the treatment of lymphomas. Annals of the New York Academy of Sciences, 1958, Apr-24, Volume: 68, Issue:3 Topics: Busulfan; Lymphoma	1958
Chemotherapy of malignant disease. II. Diseases of lymphoid tissue and bone marrow. The Medical journal of Australia, 1962, Dec-01, Volume: 49(2) Topics: Adrenal Cortex Hormones; Aged; Bone Marrow; Busulfan; Chlorambucil; Cyclophosphamide; Hodgkin Diseas	1962
[THERAPY OF HEMATODERMIAS]. La Revue du praticien, 1963, Sep-11, Volume: 13 Topics: Busulfan; Chlorambucil; Cortisone; Cyclophosphamide; Dermatology; Hydrocortisone; Leukemia; Lymphoma	1963
THE LOCAL INFLAMMATORY RESPONSE IN PATIENTS WITH BLOOD DYSCRASIAS AS TESTED BY THE SKIN WINDOW TECHNIQUE. Bulletin - Sinai Hospital of Detroit, 1963, Volume: 11 Topics: Busulfan; Hodgkin Disease; Inflammation; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukocyte	1963
[EXPERIMENTAL STUDIES ON THE ANTITUMOR EFFECT OF OLIVOMYCIN IN ASSOCIATION WITH SOME SYNTHETIC CYTOSTATIC PREPARATIONS]. Antibiotiki, 1963, Volume: 8 Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Busulfan; Cytost	1963
EXPERIMENTAL STUDY OF OLIVOMYCIN, AN ANTITUMOUR ANTIBIOTIC. Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20 Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Busulfan; Carcin	1964
THE MANAGEMENT OF MALIGNANT DISEASE OF THE HEAD AND NECK AREA IN EAST AFRICA. Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20 Topics: Africa; Africa, Eastern; Black People; Burkitt Lymphoma; Busulfan; Carcinoma, Squamous Cell; Child;	1964
THE MANAGEMENT OF LEUKEMIA AND LYMPHOMA. Applied therapeutics, 1964, Volume: 6 Topics: Adrenal Cortex Hormones; Busulfan; Chlorambucil; Cortisone; Cyclophosphamide; Hodgkin Disease; Human	1964
FURTHER OBSERVATIONS ON LATE SOMATIC EFFECTS OF RADIOMIMETIC CHEMICALS AND X-RAYS IN MICE. Cancer research, 1965, Volume: 25 Topics: Aging; Busulfan; Cataract; Female; Humans; Leukemia; Leukemia, Myeloid; Longevity; Lung Neoplasms; L	1965
ACTIVE TUBERCULOSIS IN LEUKEMIA. MALIGNANT LYMPHOMA AND MYELOFIBROSIS. Archives of pathology, 1965, Volume: 79 Topics: Alkylating Agents; Aminopterin; Busulfan; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leu	1965
GASTRIC PLASMACYTOMA (OR LYMPHOMA) FOLLOWED BY CHRONIC MYELOID LEUKAEMIA: A RARE LYMPHO-MYELO-PROLIFERATIVE DISORDER. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1965, May-22, Volume: 39 Topics: Anemia; Anemia, Macrocytic; Blood Cell Count; Busulfan; Drug Therapy; Gastrectomy; Humans; Leukemia;	1965
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin. Stem cells and development, 2005, Volume: 14, Issue:2 Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bo	2005
Further development of a model of chronic bone marrow aplasia in the busulphan-treated mouse. International journal of experimental pathology, 2006, Volume: 87, Issue:1 Topics: Anemia, Aplastic; Animals; Apoptosis; Blood Cell Count; Bone Marrow Cells; Busulfan; Dose-Response R	2006
Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. International journal of hematology, 2007, Volume: 86, Issue:3 Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; C	2007
Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer treatment reports, 1984, Volume: 68, Issue:5 Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transp	1984
Decreased tolerance to dimethyl-myleran, cyclophosphamide and radiation in lymphoma-bearing mice. European journal of cancer & clinical oncology, 1982, Volume: 18, Issue:8 Topics: Animals; Bone Marrow Transplantation; Busulfan; Colony-Forming Units Assay; Cyclophosphamide; Dose-R	1982
Concomitant myelofibrosis with agnogenic myeloid metaplasia and malignant lymphoma. Mayo Clinic proceedings, 1983, Volume: 58, Issue:9 Topics: Busulfan; Humans; Lymphoma; Male; Middle Aged; Primary Myelofibrosis	1983
Induction of lymphomas in mice by busulfan and chloramphenicol. Cancer research, 1981, Volume: 41, Issue:9 Pt 1 Topics: Animals; Busulfan; Chloramphenicol; Cocarcinogenesis; Hematocrit; Leukocyte Count; Lymphoma; Male; M	1981
Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse. Bone marrow transplantation, 1995, Volume: 15, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopterins; Bone Marr	1995
Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. Bone marrow transplantation, 1995, Volume: 15, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantati	1995
Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis. Bone marrow transplantation, 1994, Volume: 13, Issue:4 Topics: Acute Disease; Adolescent; Adult; Blood Component Transfusion; Busulfan; Combined Modality Therapy;	1994
Bone marrow transplantation in Iran. Bone marrow transplantation, 1994, Volume: 13, Issue:6 Topics: Adolescent; Adult; Anemia, Aplastic; beta-Thalassemia; Bone Marrow Transplantation; Busulfan; Child;	1994
Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children. International journal of radiation oncology, biology, physics, 1994, Apr-30, Volume: 29, Issue:1 Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide;	1994
Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies. Seminars in oncology, 1993, Volume: 20, Issue:4 Suppl 4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu	1993
Transplantation of allogeneic peripheral blood progenitor cells--the EBMT experience. Bone marrow transplantation, 1996, Volume: 17 Suppl 2 Topics: Adolescent; Adult; Blood Donors; Busulfan; Child; Child, Preschool; Cyclosporine; Erythropoietin; Fe	1996
Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. Bone marrow transplantation, 1997, Volume: 19, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan;	1997
Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. Blood, 1999, Jun-15, Volume: 93, Issue:12 Topics: Adolescent; Adult; Age Factors; Anemia, Aplastic; Body Height; Bone Marrow Transplantation; Busulfan	1999
Feasibility of autologous stem cell transplantation in chronic carriers of hepatitis B and hepatitis C virus. Leukemia & lymphoma, 2000, Volume: 36, Issue:3-4 Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Carrier State; Feasibility Studies; Female; Foll	2000
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone marrow transplantation, 2000, Volume: 25, Issue:10 Topics: Adolescent; Adult; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch	2000
Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. British journal of haematology, 2001, Volume: 114, Issue:4 Topics: Acute Disease; Adolescent; Adult; Area Under Curve; Busulfan; Drug Administration Schedule; Female;	2001
Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation. Bone marrow transplantation, 2002, Volume: 29, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Chronic Dise	2002
Dimethyl myleran and autologous marrow grafting for the treatment of spontaneous canine lymphoma. European journal of cancer, 1977, Volume: 13, Issue:12 Topics: Animals; Antibody Formation; Bone Marrow Transplantation; Busulfan; Dog Diseases; Dogs; Female; Lymp	1977
Effect of dimethylmyleran on cell-mediated immunity to a tumor allograft. Journal of the National Cancer Institute, 1975, Volume: 55, Issue:5 Topics: Animals; Busulfan; Cyclophosphamide; Cytotoxicity Tests, Immunologic; Immunity, Cellular; Immunizati	1975
Colony-stimulating activity in the serum of patients with hemopoietic malignancies after intensive chemotherapy/radiotherapy: its augmentation by GM-CSF in vivo and interleukin 4 in vitro. Experimental hematology, 1992, Volume: 20, Issue:2 Topics: Bone Marrow Cells; Busulfan; Cells, Cultured; Colony-Stimulating Factors; Combined Modality Therapy;	1992
The role of busulfan/cyclophosphamide regimens in allogeneic and autologous bone marrow transplantation. Cancer investigation, 1989, Volume: 7, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cycl	1989
New conditioning regimens for high risk marrow transplants. Bone marrow transplantation, 1989, Volume: 4 Suppl 4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu	1989
Effects of bone marrow transplantation and polyinosinic-polycytidylic acid (poly I:C) on the rescue of animals from busulfan-induced NK suppression. Experimental hematology, 1989, Volume: 17, Issue:4 Topics: Animals; Bone Marrow Transplantation; Busulfan; Cell Division; Cytotoxicity, Immunologic; Immunity,	1989
Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. Bone marrow transplantation, 1989, Volume: 4, Issue:6 Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Dr	1989
Busulfan and chloramphenicol induced T cell lymphoma: cell surface characteristics and functional properties. Clinical and experimental immunology, 1986, Volume: 64, Issue:3 Topics: Animals; Antigens, Surface; Busulfan; Cell Line; Chloramphenicol; Immunization; Killer Cells, Natura	1986
Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Annals of internal medicine, 1985, Volume: 103, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Prot	1985
Incidence and forms of leukaemia among the Congolese Bantus. Tropical and geographical medicine, 1966, Volume: 18, Issue:4 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Biopsy; Blood Protein Electrophoresis; Blood Sedimen	1966
Treatment of Moloney lymphoma with lethal doses of dimethyl-myleran combined with injections of haemopoietic cells. Lancet (London, England), 1969, Feb-01, Volume: 1, Issue:7588 Topics: Animals; Antigen-Antibody Reactions; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Femal	1969
Immunofluorescence studies in human leukemia. Blood, 1969, Volume: 34, Issue:4 Topics: Absorption; Antibodies, Anti-Idiotypic; Busulfan; Fluorescent Antibody Technique; Hodgkin Disease; H	1969
Mediastinal adenopathy in granulocytic leukemia. Archives of internal medicine, 1974, Volume: 134, Issue:1 Topics: Adult; Busulfan; Cytarabine; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid; Lymph Nodes	1974
Blood and neoplastic diseases. Rational approach to the chemotherapy of human malignant disease-II. British medical journal, 1974, Oct-26, Volume: 4, Issue:5938 Topics: Antineoplastic Agents; Brain Neoplasms; Busulfan; Cell Count; Cell Division; Cytarabine; Diffusion;	1974
Bronchial brushing in the diagnosis of pulmonary disease in patients at risk for opportunistic infection. The American review of respiratory disease, 1974, Volume: 109, Issue:3 Topics: Aspergillosis; Bacterial Infections; Biopsy; Busulfan; Chickenpox; Coccidioidomycosis; Herpes Simple	1974
Enhanced growth of transplanted tumours after treatment with cytotoxic agents. Biochemical pharmacology, 1968, Volume: 17, Issue:8 Topics: Animals; Antineoplastic Agents; Busulfan; Chlorambucil; Ethers, Cyclic; Lymphoma; Mannomustine; Meth	1968
Trephine lung biopsy with a high-speed air drill. Results of 50 biopsies in 47 patients. The Journal of thoracic and cardiovascular surgery, 1972, Volume: 64, Issue:2 Topics: Adult; Aged; Biopsy; Busulfan; Female; Humans; Lung; Lung Diseases; Lung Neoplasms; Lymphoma; Male;	1972
Some problems in the management of leukaemia and lymphoma. Proceedings of the Royal Society of Medicine, 1966, Volume: 59, Issue:12 Topics: Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Humans; Leukemia; Leukemia, Lymphoid; Leu	1966
Leukemia and lymphoma. Geriatrics, 1970, Volume: 25, Issue:12 Topics: Antineoplastic Agents; BCG Vaccine; Burkitt Lymphoma; Busulfan; Chlorambucil; Cyclophosphamide; Cyta	1970
Chemotherapy of Hodgkin's disease, lymphoma, and leukemia. Radiologic clinics of North America, 1968, Volume: 6, Issue:1 Topics: Adult; Antineoplastic Agents; Busulfan; Chlorambucil; Hodgkin Disease; Humans; Leukemia; Lymphoma; M	1968

busulfan and Germinoblastoma